Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
The purpose of this study is to observe and evaluate the efficacy and safety of HRS-4642 combined with SHR-A2102 in the treatment of advanced solid tumors
Solid Tumors
DRUG: SHR-A2102+HRS-4642
Dose Limited Toxicity(DLT), one or more unacceptable toxic reactions that occur after administration, leading to an inability to further increase the dose or extend the dosing cycle., At the end of Cycle 1 (each cycle is 14 days)|Objective Response Rate (ORR), the proportion of patients with a confirmed complete response or partial response on two consecutive occasions≥4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, up to 1 year
Progression-free Survival (PFS), the time from treatment initiation to the first disease progression or death from any cause, up to 2 year|Overall survival(OS), the time from treatment initiation until death from any reason, up to 2 year|Disease Control Rate (DCR), the proportion of patients with a best overall response of confirmed complete or partial response, or stable disease (CR+ PR + SD), up to 1 year|Duration of response (DoR), Assessed by Investigator According to RECIST v1.1, up to 1 year|Incidence and severity of adverse events (AE) and serious adverse events (SAE) and laboratory, Assess safety and tolerability by way of adverse events (CTCAE v5.0), Begin from sign the ICF until the end of the safety follow-up period，Up to approximately 2 years.
This study is a prospective, single-arm, exploratory clinical trial. It plans to enroll patients with advanced solid tumors , treating them with HRS-4642 in combination with SHR-A2102. The entire study is divided into two stages: a safety run-in period and an efficacy exploration period.